Palvella Gets FDA Priority Review for Qtorin New Drug Application

10:33 AM EDT, 10/28/2026 (MT Newswires) -- Palvella Therapeutics (PVLA) said Wednesday the US Food and Drug Administration has accepted for filing and granted priority review to its new drug application for Qtorin 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations. The FDA has assigned a target action date of Feb. 28, 2027, the company said. Palvella also said it is preparing for a potential standalone US commercial launch of Qtorin rapamycin in H1 of 2027, subject to FDA approval. Price: 134.31, Change: +1.40, Percent Change: +1.05